AIDSVAX B/B Trial Statistics

  • Volunteers completing three doses: 5,009
  • Placebo recipients: 1,679
  • AIDSVAX B/B recipients: 3,330
  • White volunteers: 4,185
  • Hispanic volunteers: 326
  • Non-white volunteers: 498
  • Black volunteers: 314
  • Annual study infection rate: 2.7%

Approximate efficacy (after at least 3 primary doses):

— All volunteers: 3.8% (p-value = 0.76)

— Non-white volunteers: 67% (p-value < 0.01)

— Black volunteers: 78% (p-value < 0.02)